export const allDrugs = [
{
    name: "Irinotecan",
    dci: "irinotécan",
    commercial: "Campto",
    administration: "IV",
    class: "Topoisomerases 1 inhibitors",
    category: "chemotherapy",
    halfLife: "14h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[228,229]"
  },
  {
    name: "Topotecan",
    dci: "topotécan",
    commercial: "Hycamtin",
    administration: "IV, Oral",
    class: "Topoisomerases 1 inhibitors",
    category: "chemotherapy",
    halfLife: "5h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[230,231]"
  },
  {
    name: "Daunorubicine",
    dci: "daunorubicine",
    commercial: "Cerubidine",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[195,232]"
  },
  {
    name: "Doxorubicine",
    dci: "doxorubicine",
    commercial: "Adriamycine",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "36 to 72h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[195,232]"
  },
  {
    name: "Epirubicine",
    dci: "épirubicine",
    commercial: "Farmorubicine",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "20 to 40h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[195,232]"
  },
  {
    name: "Idarubicine",
    dci: "idarubicine",
    commercial: "Zavedos",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "11 to 25h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[195,232]"
  },
  {
    name: "Etoposide",
    dci: "étoposide",
    commercial: "Vepeside, Celltop",
    administration: "IV, Oral",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "4 to 11h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[141]"
  },
  {
    name: "Bleomycine",
    dci: "bléomycine",
    commercial: "Bléomycine",
    administration: "IV, IM, SC",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "4h",
    normofractionatedRT: "0 (except thoracic irradiation: 24h)",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[233,234]"
  },
  {
    name: "Mercaptopurine",
    dci: "mercaptopurine",
    commercial: "Purinethol",
    administration: "Oral",
    class: "Purine analogues",
    category: "chemotherapy",
    halfLife: "2h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[245]"
  },
  {
    name: "Fludarabine",
    dci: "fludarabine",
    commercial: "Fludara",
    administration: "IV, Oral",
    class: "Purine analogues",
    category: "chemotherapy",
    halfLife: "15 to 23h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[246,247]"
  },
  {
    name: "Clofarabine",
    dci: "clofarabine",
    commercial: "Evoltra",
    administration: "IV",
    class: "Purine analogues",
    category: "chemotherapy",
    halfLife: "5.2h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[248,249]"
  },
  {
    name: "Cisplatin",
    dci: "cisplatine",
    commercial: "Cisplatine",
    administration: "IV",
    class: "Platinum based drugs",
    category: "chemotherapy",
    halfLife: "30 min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[121]"
  },
  {
    name: "Carboplatin",
    dci: "carboplatine",
    commercial: "Paraplatine",
    administration: "IV",
    class: "Platinum based drugs",
    category: "chemotherapy",
    halfLife: "6h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[156,254]"
  },
  {
    name: "Oxaliplatine",
    dci: "oxaliplatine",
    commercial: "Eloxatine",
    administration: "IV",
    class: "Platinum based drugs",
    category: "chemotherapy",
    halfLife: "25min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[155]"
  },
  {
    name: "Chlorambucil",
    dci: "chlorambucil",
    commercial: "Leukeran",
    administration: "Oral",
    class: "Nitrogen mustards",
    category: "chemotherapy",
    halfLife: "1.5h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[255]"
  },
  {
    name: "Melphalan",
    dci: "melphalan",
    commercial: "Alkeran",
    administration: "IV, Oral",
    class: "Nitrogen mustards",
    category: "chemotherapy",
    halfLife: "1.5h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[256]"
  },
  {
    name: "Cyclophosphamide",
    dci: "cyclophosphamide",
    commercial: "Endoxan",
    administration: "IV, Oral",
    class: "Nitrogen mustards",
    category: "chemotherapy",
    halfLife: "4 to 8h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[257]"
  },
  {
    name: "Ifosfamide",
    dci: "ifosfamide",
    commercial: "Holoxan",
    administration: "IV",
    class: "Nitrogen mustards",
    category: "chemotherapy",
    halfLife: "4 to 8h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[258,259]"
  },
  {
    name: "5-Fluorouracil",
    dci: "fluorouracile",
    commercial: "Fluorouracile",
    administration: "IV",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "6min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[27]"
  },
  {
    name: "Capecitabine",
    dci: "capécitabine",
    commercial: "Xeloda",
    administration: "Oral",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "3h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[27]"
  },
  {
    name: "Triflurifine",
    dci: "trifluridine",
    commercial: "Lonsurf (avec tipiracil)",
    administration: "Oral",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "1.4h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[235,236]"
  },
  {
    name: "Tipiracil",
    dci: "tipiracil",
    commercial: "Lonsurf (avec trifluridine)",
    administration: "Oral",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "1.4h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[235,236]"
  },
  {
    name: "Gemcitabine",
    dci: "gemcitabine",
    commercial: "Gemzar",
    administration: "IV",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "5 to 11h",
    normofractionatedRT: "7 days (except concurrent chemoradiation 100mg/m2)",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "0",
    references: "[237–242]"
  },
  {
    name: "Cytarabine",
    dci: "cytarabine",
    commercial: "Aracytine",
    administration: "IV, SC, IT",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "2h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[243]"
  },
  {
    name: "Azacitidine",
    dci: "azacitidine",
    commercial: "Vidaza",
    administration: "SC, IV",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "45min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "None"
  },
  {
    name: "Methotrexate",
    dci: "méthotrexate",
    commercial: "Methotrexate",
    administration: "Oral, IV, IM, IT",
    class: "Antifolates",
    category: "chemotherapy",
    halfLife: "8 to 15h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[197]"
  },
  {
    name: "Pemetrexed",
    dci: "pémétrexed",
    commercial: "Alimta",
    administration: "IV",
    class: "Antifolates",
    category: "chemotherapy",
    halfLife: "3.5h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[226]"
  },
  {
    name: "Ralitrexed",
    dci: "raltitrexed",
    commercial: "Tomudex",
    administration: "IV",
    class: "Antifolates",
    category: "chemotherapy",
    halfLife: "8 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[244]"
  },
  {
    name: "Bendamustine",
    dci: "bendamustine",
    commercial: "Levact, Bendeka",
    administration: "IV",
    class: "Nitrosea urea",
    category: "chemotherapy",
    halfLife: "30min",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[260,261]"
  },
  {
    name: "Fotemustine",
    dci: "fotémustine",
    commercial: "Muphoran",
    administration: "IV",
    class: "Nitrosea urea",
    category: "chemotherapy",
    halfLife: "30min to 2h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[262–265]"
  },
  {
    name: "Lomustine",
    dci: "lomustine",
    commercial: "Bélustine",
    administration: "Oral",
    class: "Nitrosea urea",
    category: "chemotherapy",
    halfLife: "3 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[266,267]"
  },
  {
    name: "Trabectidine",
    dci: "trabectédine",
    commercial: "Yondelis",
    administration: "IV",
    class: "Alcaloid",
    category: "chemotherapy",
    halfLife: "7.5 days",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[268,269]"
  },
  {
    name: "Dacarbazine",
    dci: "dacarbazine",
    commercial: "Déticène",
    administration: "IV",
    class: "Various",
    category: "chemotherapy",
    halfLife: "1.5h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[273]"
  },
  {
    name: "Procarbazine",
    dci: "procarbazine",
    commercial: "Natulan",
    administration: "Oral",
    class: "Various",
    category: "chemotherapy",
    halfLife: "7 min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[274–276]"
  },
  {
    name: "Mitomycin C",
    dci: "mitomycine",
    commercial: "Amétycine",
    administration: "IV, Intravésical",
    class: "Various",
    category: "chemotherapy",
    halfLife: "1h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[172,174]"
  },
  {
    name: "Temozolomide",
    dci: "témozolomide",
    commercial: "Temodal",
    administration: "Oral, IV",
    class: "Various",
    category: "chemotherapy",
    halfLife: "1.8h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[115]"
  },
  {
    name: "Hydroxyurea",
    dci: "hydroxyurée",
    commercial: "Hydrea",
    administration: "Oral",
    class: "Various",
    category: "chemotherapy",
    halfLife: "5h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[250–252]"
  },
  {
    name: "Mycophenolate mofetil",
    dci: "mycophénolate mofétil",
    commercial: "Cellcept",
    administration: "Oral",
    class: "Various",
    category: "chemotherapy",
    halfLife: "11 to 18h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[253]"
  },
  {
    name: "Busulfan",
    dci: "busulfan",
    commercial: "Busilvex",
    administration: "IV",
    class: "Various",
    category: "chemotherapy",
    halfLife: "2.8 to 3.9h",
    normofractionatedRT: "No concomitant association: an expert opinion is required before irradiation",
    palliativeRT: "No concomitant association: an expert opinion is required before irradiation",
    stereotacticRT: "No concomitant association: an expert opinion is required before irradiation",
    intracranialRT: "No concomitant association: an expert opinion is required before irradiation",
    references: "[270–272]"
  },
  {
    name: "Paclitaxel",
    dci: "paclitaxel",
    commercial: "Taxol",
    administration: "IV",
    class: "Taxanes",
    category: "chemotherapy",
    halfLife: "24h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[277–279]"
  },
  {
    name: "Nab-Paclitaxel",
    dci: "paclitaxel (nanoparticules d'albumine)",
    commercial: "Abraxane",
    administration: "IV",
    class: "Taxanes",
    category: "chemotherapy",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[280–282]"
  },
  {
    name: "Docetaxel",
    dci: "docétaxel",
    commercial: "Taxotère",
    administration: "IV",
    class: "Taxanes",
    category: "chemotherapy",
    halfLife: "11 to 17h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[47]"
  },
  {
    name: "Cabazitaxel",
    dci: "cabazitaxel",
    commercial: "Jevtana",
    administration: "IV",
    class: "Taxanes",
    category: "chemotherapy",
    halfLife: "96h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[283]"
  },
  {
    name: "Eribuline",
    dci: "éribuline",
    commercial: "Halaven",
    administration: "IV",
    class: "Halichondrins",
    category: "chemotherapy",
    halfLife: "40h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "0",
    references: "[284]"
  },
  {
    name: "Vinblastine",
    dci: "vinblastine",
    commercial: "Velbé",
    administration: "IV",
    class: "Vinca alkaloids",
    category: "chemotherapy",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[285,286]"
  },
  {
    name: "Vincristine",
    dci: "vincristine",
    commercial: "Oncovin",
    administration: "IV",
    class: "Vinca alkaloids",
    category: "chemotherapy",
    halfLife: "3.5 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[287]"
  },
  {
    name: "Vinorelbine",
    dci: "vinorelbine",
    commercial: "Navelbine",
    administration: "IV, Oral",
    class: "Vinca alkaloids",
    category: "chemotherapy",
    halfLife: "40h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[288,289]"
  },
  {
    name: "Goserelin",
    dci: "goséréline",
    commercial: "Zoladex",
    administration: "SC (implant)",
    class: "LH-RH agonists",
    category: "endocrine",
    halfLife: "7h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[290–292]"
  },
  {
    name: "Leuproprelin",
    dci: "leuproréline",
    commercial: "Eligard, Enantone",
    administration: "SC, IM",
    class: "LH-RH agonists",
    category: "endocrine",
    halfLife: "3h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[293]"
  },
  {
    name: "Triptoreline",
    dci: "triptoréline",
    commercial: "Décapeptyl",
    administration: "IM, SC",
    class: "LH-RH agonists",
    category: "endocrine",
    halfLife: "5h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[294]"
  },
  {
    name: "Degarelix",
    dci: "dégarélix",
    commercial: "Firmagon",
    administration: "SC",
    class: "LH-RH antagonists",
    category: "endocrine",
    halfLife: "28 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[295]"
  },
  {
    name: "Relugolix",
    dci: "rélugolix",
    commercial: "Orgovyx, Relumina",
    administration: "Oral",
    class: "LH-RH antagonists",
    category: "endocrine",
    halfLife: "61.5h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[296]"
  },
  {
    name: "Bicalutamide",
    dci: "bicalutamide",
    commercial: "Casodex",
    administration: "Oral",
    class: "Anti-androgens receptor",
    category: "endocrine",
    halfLife: "7 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[297]"
  },
  {
    name: "Apalutamide",
    dci: "apalutamide",
    commercial: "Erleada",
    administration: "Oral",
    class: "Anti-androgens receptor",
    category: "endocrine",
    halfLife: "72h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[298,299]"
  },
  {
    name: "Enzalutamide",
    dci: "enzalutamide",
    commercial: "Xtandi",
    administration: "Oral",
    class: "Anti-androgens receptor",
    category: "endocrine",
    halfLife: "6 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[300]"
  },
  {
    name: "Darolutamide",
    dci: "darolutamide",
    commercial: "Nubeqa",
    administration: "Oral",
    class: "Anti-androgens receptor",
    category: "endocrine",
    halfLife: "20h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[301]"
  },
  {
    name: "Abiraterone acetate",
    dci: "acétate d'abiratérone",
    commercial: "Zytiga",
    administration: "Oral",
    class: "Cytochrome P450 C17 inhibitor",
    category: "endocrine",
    halfLife: "15h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[302,303]"
  },
  {
    name: "Tamoxifene",
    dci: "tamoxifène",
    commercial: "Nolvadex",
    administration: "Oral",
    class: "Anti estrogens receptor",
    category: "endocrine",
    halfLife: "7 days",
    normofractionatedRT: "0 (except intrinsic radiosensitivity)",
    palliativeRT: "0 (except intrinsic radiosensitivity)",
    stereotacticRT: "0 (except intrinsic radiosensitivity)",
    intracranialRT: "0 (except intrinsic radiosensitivity)",
    references: "[60–64]"
  },
  {
    name: "Fulvestrant",
    dci: "fulvestrant",
    commercial: "Faslodex",
    administration: "IM",
    class: "Anti estrogens receptor",
    category: "endocrine",
    halfLife: "50 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[304,305]"
  },
  {
    name: "Letrozole",
    dci: "létrozole",
    commercial: "Femara",
    administration: "Oral",
    class: "Anti-aromatases",
    category: "endocrine",
    halfLife: "2 to 4 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[67,68]"
  },
  {
    name: "Anastrozole",
    dci: "anastrozole",
    commercial: "Arimidex",
    administration: "Oral",
    class: "Anti-aromatases",
    category: "endocrine",
    halfLife: "48h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[306]"
  },
  {
    name: "Exemestane",
    dci: "exémestane",
    commercial: "Aromasine",
    administration: "Oral",
    class: "Anti-aromatases",
    category: "endocrine",
    halfLife: "24h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[65]"
  },
  {
    name: "Megestrol acetate",
    dci: "acétate de mégestrol",
    commercial: "Megace",
    administration: "Oral",
    class: "Analogues of progesterone",
    category: "endocrine",
    halfLife: "20h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[307,308]"
  },
  {
    name: "Alectinib",
    dci: "alectinib",
    commercial: "Alecensa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "32h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[207]"
  },
  {
    name: "Brigatinib",
    dci: "brigatinib",
    commercial: "Alunbrig",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[207]"
  },
  {
    name: "Ceritinib",
    dci: "céritinib",
    commercial: "Zykadia",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "40h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[207,309]"
  },
  {
    name: "Crizotinib",
    dci: "crizotinib",
    commercial: "Xalkori",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "42h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[310–312]"
  },
  {
    name: "Lorlatinib",
    dci: "lorlatinib",
    commercial: "Lorviqua",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (ALK)",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[208]"
  },
  {
    name: "Bosutinib",
    dci: "bosutinib",
    commercial: "Bosulif",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BCR-ABL)",
    category: "targeted",
    halfLife: "35h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Dasatinib",
    dci: "dasatinib",
    commercial: "Sprycel",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BCR-ABL)",
    category: "targeted",
    halfLife: "5h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[313,314]"
  },
  {
    name: "Imatinib",
    dci: "imatinib",
    commercial: "Glivec",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BCR-ABL)",
    category: "targeted",
    halfLife: "18h",
    normofractionatedRT: "4 days",
    palliativeRT: "4 days",
    stereotacticRT: "4 days",
    intracranialRT: "4 days",
    references: "[315]"
  },
  {
    name: "Nilotinib",
    dci: "nilotinib",
    commercial: "Tasigna",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BCR-ABL)",
    category: "targeted",
    halfLife: "17h",
    normofractionatedRT: "4 days",
    palliativeRT: "4 days",
    stereotacticRT: "4 days",
    intracranialRT: "4 days",
    references: "[316]"
  },
  {
    name: "Ponatinib",
    dci: "ponatinib",
    commercial: "Iclusig",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BCR-ABL)",
    category: "targeted",
    halfLife: "22h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Acalabrutinib",
    dci: "acalabrutinib",
    commercial: "Calquence",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BTK)",
    category: "targeted",
    halfLife: "7h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "None"
  },
  {
    name: "Ibrutinib",
    dci: "ibrutinib",
    commercial: "Imbruvica",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BTK)",
    category: "targeted",
    halfLife: "4h to 13h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[319,320]"
  },
  {
    name: "Pirtobrutinib",
    dci: "pirtobrutinib",
    commercial: "Jaypirca",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BTK)",
    category: "targeted",
    halfLife: "19h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Zanubrutinib",
    dci: "zanubrutinib",
    commercial: "Brukinsa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BTK)",
    category: "targeted",
    halfLife: "4h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "None"
  },
  {
    name: "Afatinib",
    dci: "afatinib",
    commercial: "Giotrif",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (EGFR)",
    category: "targeted",
    halfLife: "37h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "0",
    references: "[323]"
  },
  {
    name: "Gefitinib",
    dci: "géfitinib",
    commercial: "Iressa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (EGFR)",
    category: "targeted",
    halfLife: "41h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[327]"
  },
  {
    name: "Erlotinib",
    dci: "erlotinib",
    commercial: "Tarceva",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (EGFR)",
    category: "targeted",
    halfLife: "36h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[326]"
  },
  {
    name: "Osimertinib",
    dci: "osimertinib",
    commercial: "Tagrisso",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (EGFR)",
    category: "targeted",
    halfLife: "48h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[82,83,328,329]"
  },
  {
    name: "Futibatinib",
    dci: "futibatinib",
    commercial: "Lytgobi",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (FGFR)",
    category: "targeted",
    halfLife: "3h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "None"
  },
  {
    name: "Pemigatinib",
    dci: "pémigatinib",
    commercial: "Pemazyre",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (FGFR2)",
    category: "targeted",
    halfLife: "15h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Gilteritinib",
    dci: "giltéritinib",
    commercial: "Xospata",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (FLT3)",
    category: "targeted",
    halfLife: "4.7 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Lapatinib",
    dci: "lapatinib",
    commercial: "Tyverb",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (HER2)",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[91,330]"
  },
  {
    name: "Tucatinib",
    dci: "tucatinib",
    commercial: "Tukysa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (HER2)",
    category: "targeted",
    halfLife: "8.5h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[331,332]"
  },
  {
    name: "Fedratinib",
    dci: "fédratinib",
    commercial: "Inrebic",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (JAK)",
    category: "targeted",
    halfLife: "4.75 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Ruxolitinib",
    dci: "ruxolitinib",
    commercial: "Jakavi",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (JAK)",
    category: "targeted",
    halfLife: "3h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[333]"
  },
  {
    name: "Binimetinib",
    dci: "binimétinib",
    commercial: "Mektovi",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MEK)",
    category: "targeted",
    halfLife: "8.66h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[216]"
  },
  {
    name: "Cobimetinib",
    dci: "cobimétinib",
    commercial: "Cotellic",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MEK)",
    category: "targeted",
    halfLife: "43h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[334]"
  },
  {
    name: "Trametinib",
    dci: "tramétinib",
    commercial: "Mekinist",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MEK)",
    category: "targeted",
    halfLife: "127h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[334–336]"
  },
  {
    name: "Capmatinib",
    dci: "capmatinib",
    commercial: "Tabrecta",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MET)",
    category: "targeted",
    halfLife: "6.5h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[337]"
  },
  {
    name: "Cabozantinib",
    dci: "cabozantinib",
    commercial: "Cabometyx, Cometriq",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MET, RET, ROS1, VEGFR)",
    category: "targeted",
    halfLife: "4.5 days",
    normofractionatedRT: "21 days",
    palliativeRT: "0 (except abdomino pelvic)",
    stereotacticRT: "21 days",
    intracranialRT: "0",
    references: "[338–340]"
  },
  {
    name: "Tepotinib",
    dci: "tépotinib",
    commercial: "Tepmetko",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MET)",
    category: "targeted",
    halfLife: "32h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Selpercatinib",
    dci: "selpercatinib",
    commercial: "Retsevmo",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (RET fusion)",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Larotrectinib",
    dci: "larotrectinib",
    commercial: "Vitrakvi",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (TRK)",
    category: "targeted",
    halfLife: "3h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[342]"
  },
  {
    name: "Axitinib",
    dci: "axitinib",
    commercial: "Inlyta",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (VEGFR)",
    category: "targeted",
    halfLife: "2.5h to 6h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[343–346]"
  },
  {
    name: "Lenvatinib",
    dci: "lenvatinib",
    commercial: "Lenvima, Kisplyx",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (c-Kit, FGFR, PDGFR, VEGFR)",
    category: "targeted",
    halfLife: "28h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[347,348]"
  },
  {
    name: "Sorafenib",
    dci: "sorafénib",
    commercial: "Nexavar",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (c-Kit, FLT3, PDGFR, VEGFR)",
    category: "targeted",
    halfLife: "24h to 48h",
    normofractionatedRT: "7 days",
    palliativeRT: "0 (except abdomino pelvic)",
    stereotacticRT: "7 days",
    intracranialRT: "0",
    references: "[351]"
  },
  {
    name: "Pazopanib",
    dci: "pazopanib",
    commercial: "Votrient",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (c-Kit)",
    category: "targeted",
    halfLife: "31h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[321,322]"
  },
  {
    name: "Ripretinib",
    dci: "riprétinib",
    commercial: "Qinlock",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (c-Kit)",
    category: "targeted",
    halfLife: "15h",
    normofractionatedRT: "3 days",
    palliativeRT: "3 days",
    stereotacticRT: "3 days",
    intracranialRT: "3 days",
    references: "None"
  },
  {
    name: "Sunitinib",
    dci: "Sunitinib",
    commercial: "Sutent",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (FLT3, PDGFR, RET, VEGFR)",
    category: "targeted",
    halfLife: "4.5 days",
    normofractionatedRT: "21 days",
    palliativeRT: "0 (except abdomino pelvic)",
    stereotacticRT: "21 days",
    intracranialRT: "0",
    references: "[352]"
  },
  {
    name: "Obinutuzumab",
    dci: "obinutuzumab",
    commercial: "Gazyvaro",
    administration: "IV",
    class: "Monoclonal antibodies (CD20)",
    category: "targeted",
    halfLife: "23.9 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[386]"
  },
  {
    name: "Rituximab",
    dci: "rituximab",
    commercial: "MabThera, Rituxan",
    administration: "IV, SC",
    class: "Monoclonal antibodies (CD20)",
    category: "targeted",
    halfLife: "22 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[387]"
  },
  {
    name: "Cetuximab",
    dci: "cétuximab",
    commercial: "Erbitux",
    administration: "IV",
    class: "Monoclonal antibodies (EGFR)",
    category: "targeted",
    halfLife: "4 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[130]"
  },
  {
    name: "Panitumumab",
    dci: "panitumumab",
    commercial: "Vectibix",
    administration: "IV",
    class: "Monoclonal antibodies (EGFR)",
    category: "targeted",
    halfLife: "7 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[177,389]"
  },
  {
    name: "Pertuzumab",
    dci: "pertuzumab",
    commercial: "Perjeta",
    administration: "IV",
    class: "Monoclonal antibodies (HER2)",
    category: "targeted",
    halfLife: "18 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[91,390–392]"
  },
  {
    name: "Trastuzumab",
    dci: "trastuzumab",
    commercial: "Herceptin",
    administration: "IV, SC",
    class: "Monoclonal antibodies (HER2)",
    category: "targeted",
    halfLife: "28.5 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[91,390]"
  },
  {
    name: "Bevacizumab",
    dci: "bévacizumab",
    commercial: "Avastin",
    administration: "IV",
    class: "Monoclonal antibodies (VEGFR)",
    category: "targeted",
    halfLife: "18 to 20 days",
    normofractionatedRT: "21 days",
    palliativeRT: "0 (except abdomino pelvic)",
    stereotacticRT: "21 days",
    intracranialRT: "0",
    references: "[200–202,393]"
  },
  {
    name: "Ramucirumab",
    dci: "ramucirumab",
    commercial: "Cyramza",
    administration: "IV",
    class: "Monoclonal antibodies (VEGFR)",
    category: "targeted",
    halfLife: "14 days",
    normofractionatedRT: "21 days",
    palliativeRT: "0 (except abdomino pelvic)",
    stereotacticRT: "21 days",
    intracranialRT: "0",
    references: "[394,395]"
  },
  {
    name: "Daratumumab",
    dci: "daratumumab",
    commercial: "Darzalex",
    administration: "IV, SC",
    class: "Monoclonal antibodies (CD38)",
    category: "targeted",
    halfLife: "9 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[373]"
  },
  {
    name: "Venetoclax",
    dci: "vénétoclax",
    commercial: "Venclyxto",
    administration: "Oral",
    class: "Bcl-2 inhibitors",
    category: "targeted",
    halfLife: "26h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[353]"
  },
  {
    name: "Dabrafenib",
    dci: "dabrafénib",
    commercial: "Tafinlar",
    administration: "Oral",
    class: "BRAF inhibitors",
    category: "targeted",
    halfLife: "2.6h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[216]"
  },
  {
    name: "Encorafenib",
    dci: "encorafénib",
    commercial: "Braftovi",
    administration: "Oral",
    class: "BRAF inhibitors",
    category: "targeted",
    halfLife: "6.3h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[317]"
  },
  {
    name: "Vemurafenib",
    dci: "vémurafénib",
    commercial: "Zelboraf",
    administration: "Oral",
    class: "BRAF inhibitors",
    category: "targeted",
    halfLife: "51h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[318]"
  },
  {
    name: "Niraparib",
    dci: "niraparib",
    commercial: "Zejula",
    administration: "Oral",
    class: "PARP inhibitors",
    category: "targeted",
    halfLife: "48h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[359]"
  },
  {
    name: "Olaparib",
    dci: "olaparib",
    commercial: "Lynparza",
    administration: "Oral",
    class: "PARP inhibitors",
    category: "targeted",
    halfLife: "15h",
    normofractionatedRT: "3 days",
    palliativeRT: "0",
    stereotacticRT: "3 days",
    intracranialRT: "3 days",
    references: "[360,361]"
  },
  {
    name: "Rucaparib",
    dci: "rucaparib",
    commercial: "Rubraca",
    administration: "Oral",
    class: "PARP inhibitors",
    category: "targeted",
    halfLife: "26h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[360]"
  },
  {
    name: "Talazoparib",
    dci: "talazoparib",
    commercial: "Talzenna",
    administration: "Oral",
    class: "PARP inhibitors",
    category: "targeted",
    halfLife: "3.75 days",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[362]"
  },
  {
    name: "Bortezomib",
    dci: "bortézomib",
    commercial: "Velcade",
    administration: "IV, SC",
    class: "Proteasome inhibitors",
    category: "targeted",
    halfLife: "40 to 193h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[363–365]"
  },
  {
    name: "Carfilzomib",
    dci: "carfilzomib",
    commercial: "Kyprolis",
    administration: "IV",
    class: "Proteasome inhibitors",
    category: "targeted",
    halfLife: "1h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "None"
  },
  {
    name: "Ixazomib",
    dci: "ixazomib",
    commercial: "Ninlaro",
    administration: "Oral",
    class: "Proteasome inhibitors",
    category: "targeted",
    halfLife: "9.5 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "None"
  },
  {
    name: "Vismodegib",
    dci: "vismodégib",
    commercial: "Erivedge",
    administration: "Oral",
    class: "SMO protein inhibitors",
    category: "targeted",
    halfLife: "4 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[366,367]"
  },
  {
    name: "Sonidegib",
    dci: "sonidégib",
    commercial: "Odomzo",
    administration: "Oral",
    class: "SMO protein inhibitors",
    category: "targeted",
    halfLife: "28 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[368]"
  },
  {
    name: "Alpelisib",
    dci: "alpélisib",
    commercial: "Piqray",
    administration: "Oral",
    class: "PI3K inhibitors",
    category: "targeted",
    halfLife: "9h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[369]"
  },
  {
    name: "Idelalisib",
    dci: "idélalisib",
    commercial: "Zydelig",
    administration: "Oral",
    class: "PI3K inhibitors",
    category: "targeted",
    halfLife: "8h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[370]"
  },
  {
    name: "Everolimus",
    dci: "évérolimus",
    commercial: "Afinitor",
    administration: "Oral",
    class: "mTOR inhibitors",
    category: "targeted",
    halfLife: "30h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[382–384]"
  },
  {
    name: "Sirolimus",
    dci: "sirolimus",
    commercial: "Rapamune",
    administration: "Oral",
    class: "mTOR inhibitors",
    category: "targeted",
    halfLife: "62h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[379–381]"
  },
  {
    name: "Ciclosporin",
    dci: "ciclosporine",
    commercial: "Neoral",
    administration: "Oral",
    class: "Anti calcineurins",
    category: "targeted",
    halfLife: "6-20h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[377]"
  },
  {
    name: "Tacrolimus",
    dci: "tacrolimus",
    commercial: "Prograf",
    administration: "Oral",
    class: "Anti calcineurins",
    category: "targeted",
    halfLife: "15h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[378]"
  },
  {
    name: "Vandetanib",
    dci: "vandétanib",
    commercial: "Caprelsa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (EGFR, VEGFR)",
    category: "targeted",
    halfLife: "19 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[228]"
  },
  {
    name: "Abemaciclib",
    dci: "abémaciclib",
    commercial: "Verzenios",
    administration: "Oral",
    class: "CDK4/6 inhibitors",
    category: "targeted",
    halfLife: "25h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[91,354]"
  },
  {
    name: "Palbociclib",
    dci: "palbociclib",
    commercial: "Ibrance",
    administration: "Oral",
    class: "CDK4/6 inhibitors",
    category: "targeted",
    halfLife: "29h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[91,354]"
  },
  {
    name: "Ribociclib",
    dci: "ribociclib",
    commercial: "Kisqali",
    administration: "Oral",
    class: "CDK4/6 inhibitors",
    category: "targeted",
    halfLife: "30 to 55h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[91,354,355]"
  },
  {
    name: "Vorinostat",
    dci: "vorinostat",
    commercial: "Zolinza",
    administration: "Oral",
    class: "Histones deacetylases HDAC inhibitors",
    category: "targeted",
    halfLife: "2h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[356]"
  },
  {
    name: "Panobinostat",
    dci: "panobinostat",
    commercial: "Farydak",
    administration: "Oral",
    class: "Histones deacetylases HDAC inhibitors",
    category: "targeted",
    halfLife: "37h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[357]"
  },
  {
    name: "Ivosidenib",
    dci: "ivosidénib",
    commercial: "Tibsovo",
    administration: "Oral",
    class: "Isocitrate dehydrogenase inhibitors (IDH-1)",
    category: "targeted",
    halfLife: "58h to 129h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[358]"
  },
  {
    name: "Enasidenib",
    dci: "énasidénib",
    commercial: "Idhifa",
    administration: "Oral",
    class: "Isocitrate dehydrogenase inhibitors (IDH-2)",
    category: "targeted",
    halfLife: "8 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Adagrasib",
    dci: "adagrasib",
    commercial: "Krazati",
    administration: "Oral",
    class: "KRAS G12C inhibitors",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "None"
  },
  {
    name: "Sotorasib",
    dci: "sotorasib",
    commercial: "Lumykras",
    administration: "Oral",
    class: "KRAS G12C inhibitors",
    category: "targeted",
    halfLife: "5h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "None"
  },
  {
    name: "Brentuximab vedotin",
    dci: "brentuximab védotine",
    commercial: "Adcetris",
    administration: "IV",
    class: "Antibody-drug conjugates (CD30)",
    category: "targeted",
    halfLife: "4 to 6 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[396,397]"
  },
  {
    name: "Trastuzumab Emtansine",
    dci: "trastuzumab emtansine",
    commercial: "Kadcyla",
    administration: "IV",
    class: "Antibody-drug conjugates (HER2)",
    category: "targeted",
    halfLife: "4 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "7 days",
    references: "[91]"
  },
  {
    name: "Trastuzumab Deruxtecan",
    dci: "trastuzumab déruxtécan",
    commercial: "Enhertu",
    administration: "IV",
    class: "Antibody-drug conjugates",
    category: "targeted",
    halfLife: "7 days",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[398]"
  },
  {
    name: "Enfortumab Vedotin",
    dci: "enfortumab védotine",
    commercial: "Padcev",
    administration: "IV",
    class: "Antibody-drug conjugates (Nectin 4)",
    category: "targeted",
    halfLife: "3.6 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[399,400]"
  },
  {
    name: "Sacituzumab govitecan",
    dci: "sacituzumab govitécan",
    commercial: "Trodelvy",
    administration: "IV",
    class: "Antibody-drug conjugates (TROP2)",
    category: "targeted",
    halfLife: "15h to 19h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[401,402]"
  },
  {
    name: "Aflibercept",
    dci: "aflibercept",
    commercial: "Zaltrap",
    administration: "IV",
    class: "Recombinant fusion protein (VEGF)",
    category: "targeted",
    halfLife: "6 days",
    normofractionatedRT: "21 days",
    palliativeRT: "0 (except abdomino pelvic)",
    stereotacticRT: "21 days",
    intracranialRT: "0",
    references: "[204,385]"
  },
  {
    name: "Lenalidomide",
    dci: "lénalidomide",
    commercial: "Revlimid",
    administration: "Oral",
    class: "Immunomodulators",
    category: "immunotherapy",
    halfLife: "3h to 5h",
    normofractionatedRT: "24h",
    palliativeRT: "24h",
    stereotacticRT: "24h",
    intracranialRT: "24h",
    references: "[371,372]"
  },
  {
    name: "Pomalidomide",
    dci: "pomalidomide",
    commercial: "Imnovid",
    administration: "Oral",
    class: "Immunomodulators",
    category: "immunotherapy",
    halfLife: "9h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[373]"
  },
  {
    name: "Thalidomide",
    dci: "thalidomide",
    commercial: "Thalidomide",
    administration: "Oral",
    class: "Immunomodulators",
    category: "immunotherapy",
    halfLife: "7h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[374–376]"
  },
  {
    name: "Nivolumab",
    dci: "nivolumab",
    commercial: "Opdivo",
    administration: "IV",
    class: "PD1 inhibitors",
    category: "immunotherapy",
    halfLife: "25 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[405,406]"
  },
  {
    name: "Pembrolizumab",
    dci: "pembrolizumab",
    commercial: "Keytruda",
    administration: "IV",
    class: "PD1 inhibitors",
    category: "immunotherapy",
    halfLife: "22 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[407,408]"
  },
  {
    name: "Cemiplimab",
    dci: "cemiplimab",
    commercial: "Libtayo",
    administration: "IV",
    class: "PD1 inhibitors",
    category: "immunotherapy",
    halfLife: "20 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[403]"
  },
  {
    name: "Dostarlimab",
    dci: "dostarlimab",
    commercial: "Jemperli",
    administration: "IV",
    class: "PD1 inhibitors",
    category: "immunotherapy",
    halfLife: "25 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[404]"
  },
  {
    name: "Atezolizumab",
    dci: "atézolizumab",
    commercial: "Tecentriq",
    administration: "IV",
    class: "PDL1 inhibitors",
    category: "immunotherapy",
    halfLife: "27 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[409,410]"
  },
  {
    name: "Avelumab",
    dci: "avélumab",
    commercial: "Bavencio",
    administration: "IV",
    class: "PDL1 inhibitors",
    category: "immunotherapy",
    halfLife: "6 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[411,412]"
  },
  {
    name: "Durvalumab",
    dci: "durvalumab",
    commercial: "Imfinzi",
    administration: "IV",
    class: "PDL1 inhibitors",
    category: "immunotherapy",
    halfLife: "18 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[413]"
  },
  {
    name: "Ipilimumab",
    dci: "ipilimumab",
    commercial: "Yervoy",
    administration: "IV",
    class: "CTLA4 inhibitors",
    category: "immunotherapy",
    halfLife: "15 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[414,415]"
  },
  {
    name: "Tremelimumab",
    dci: "trémélimumab",
    commercial: "Imjudo",
    administration: "IV",
    class: "CTLA4 inhibitors",
    category: "immunotherapy",
    halfLife: "14.2 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[416,417]"
  }
];